Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mereo Biopharma Group Plc ADR (MREO)

Mereo Biopharma Group Plc ADR (MREO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Mereo Biopharma Group Plc ADR ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G 0QF GBR

www.mereobiopharma.com Employees: 36 P: 44-33-3023-7300

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company's rare disease product candidates, setrusumab for the treatment of osteogenesis imperfecta and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease. Mereo BioPharma Group plc is based in LONDON.

Key Statistics

Overview:

Market Capitalization, $K 106,698
Enterprise Value, $K 36,898
Shares Outstanding, K 159,132
Float, K 150,380
% Float 94.50%
Short Interest, K 9,785
Short Float 6.15%
Days to Cover 3.35
Short Volume Ratio 0.34
% of Insider Shareholders 5.50%
% of Institutional Shareholders 62.83%
Annual Net Income, $ -43,250 K
Last Quarter Sales, $ 500 K
Last Quarter Net Income, $ -14,620 K
EBIT, $ -46,350 K
EBITDA, $ -45,770 K
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 97.59%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.01 on 11/10/25
Next Earnings Date 03/25/26
Earnings Per Share ttm -0.07
EPS Growth vs. Prev Qtr 50.00%
EPS Growth vs. Prev Year 50.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

MREO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -74.97%
Return-on-Assets % -63.73%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales 212.09
Price/Cash Flow N/A
Price/Book 2.45
Book Value/Share 0.34
Interest Coverage -30.57
60-Month Beta 0.42
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar